7 Green Days In A Row: Regeneron Pharmaceuticals Stock Is Up 17%
A sustained run in the biotech name has investors looking closer at the numbers behind the momentum.
Regeneron Pharmaceuticals (REGN) stock has now moved higher for 7 consecutive trading days. The cumulative gain over this period is 17%, a move that has added about $11 billion to the company’s market value.
For shareholders, this run has pushed the company’s total market capitalization to about $78 billion. The advance has occurred while the broader market has been flat, suggesting the move is specific to the company.
The Streak Next To The S&P 500
Here is how REGN stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | REGN | S&P 500 |
|---|---|---|
| 1D | 3.3% | 0.7% |
| 7D (Current Streak) | 17.1% | -0.1% |
| 1M (21D) | 22.1% | 0.1% |
| 3M (63D) | 8.0% | 3.9% |
| YTD 2026 | -0.9% | 9.4% |
| 2025 | 9.0% | 16.4% |
| 2024 | -18.9% | 23.3% |
| 2023 | 21.7% | 24.2% |
The Run Is Backed By Stronger-Than-Average Fundamentals.
This streak is happening against a backdrop of solid operating metrics. Regeneron’s revenue over the last twelve months grew 9.3%, ahead of the S&P 500 median of 7.8%. Its operating margin of 26.9% is also well above the S&P 500 median of 18.4%. The stock’s price-to-earnings multiple of 18.1 is currently below the median of 23.9 for the index.
The move is also the stock’s own story, as the S&P 500 returned -0.1% over the same 7 trading days. In the current market, such winning streaks are uncommon; only 18 S&P 500 stocks are on winning streaks of 3 days or more, while 88 are on losing streaks.
A Streak Is Information, Not An Instruction.
A multi-day run is a clear signal of investor attention and momentum. But all streaks end, and a chart pattern alone is never a complete thesis. The disciplined approach is to use the new price as a prompt to re-evaluate the underlying business.
The data shows a company with above-average growth and profitability trading at a below-average valuation multiple relative to the market. That is the kind of fundamental picture that warrants a closer look, which is precisely what a streak invites you to do.
If you are hunting for strength that has more behind it than a hot tape, our Guidance Momentum screen surfaces the names where management raised its own outlook, which is the kind of momentum that tends to persist.
Prefer the theme to this single name? A biotech ETF like IBB owns the whole group. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
One Hot Stock Is A Story. Thirty Sound Ones Are A Strategy
A streak like this earns a place on your watchlist, and it also earns a question: how much of your outcome do you want depending on one company keeping this up?
The Trefis High Quality (HQ) Portfolio answers it with breadth: roughly 30 businesses picked for consistent cash generation, strong margins, and balance-sheet strength, sized and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Follow the story; invest in the strategy.